ABSTRACT: Pyrazinamide (PZA) is a critical component of first-and second-line treatments of tuberculosis (TB), yet its mechanism of action largely remains an enigma. We carried out a genetic screen to isolate Mycobacterium bovis BCG mutants resistant to pyrazinoic acid (POA), the bioactive derivative of PZA, followed by whole genome sequencing of 26 POA resistant strains. Rather than finding mutations in the proposed candidate targets fatty acid synthase I and ribosomal protein S1, we found resistance conferring mutations in two pathways: missense mutations in aspartate decarboxylase panD, involved in the synthesis of the essential acyl carrier coenzyme A (CoA), and frameshift mutations in the vitro nonessential polyketide synthase genes mas and ppsA-E, involved in the synthesis of the virulence factor phthiocerol dimycocerosate (PDIM). Probing for cross resistance to two structural analogs of POA, nicotinic acid and benzoic acid, showed that the analogs share the PDIM-but not the CoA-related mechanism of action with POA. We demonstrated that POA depletes CoA in wild-type bacteria, which is prevented by mutations in panD. Sequencing 10 POA-resistant Mycobacterium tuberculosis H37Rv isolates confirmed the presence of at least 2 distinct mechanisms of resistance to the drug. The emergence of resistance through the loss of a virulence factor in vitro may explain the lack of clear molecular patterns in PZA-resistant clinical isolates, other than mutations in the prodrug-converting enzyme. The apparent interference of POA with virulence pathways may contribute to the drug's excellent in vivo efficacy compared to its modest in vitro potency.
PZA is a critical component of the current first-line regimen for treating TB. Its inclusion in the regimen in the 1980s resulted in dramatically shortening the duration of therapy from 12 to 6 months; i.e., PZA is a key sterilizing drug. 1 The current 6-month regimen is still too lengthy to ensure compliance, not only affecting cure rates but also facilitating the development of drug resistance. Treatment shortening to 2 months or less is therefore a major goal in TB drug development. 2 Most new drug combinations currently in preclinical and clinical development include PZA, 3 although its mechanism of action remains illdefined. Considering the clinically proven sterilizing activity of PZA, the identification of its target(s) may provide clues and effective approaches for the discovery of shortened chemotherapeutic regimens.
PZA is a prodrug that requires hydrolysis to the bioactive form, pyrazinoic acid (POA). Prodrug conversion is carried out by the bacterial amidase PncA, the inactivation of which causes resistance in vitro, 4 and also by host enzymes. 5 Until recently, it was believed that PZA/POA is active in vitro under acidic conditions only. Extracellular low pH was part of the suggested mechanism of action of the drug: POA, a low-molecular-weight carboxylic acid, was thought to act as an ionophore affecting membrane energetics and causing intracellular acidification. 6, 7 On the basis of these in vitro findings, it was assumed that TB lesions must be acidic to allow PZA to be active in vivo. 1, 8 In addition, two discrete molecular targets were suggested to be inhibited by the drug. POA was shown to block fatty acid synthesis, and fatty acid synthase I (FAS I) was suggested as the target of the drug. 9 FAS I as a direct target of POA was called into question by subsequent works. 10 Protein-binding studies found a large number of POA-binding partners, one of which was identified to be the 30S ribosomal S1/RpsA protein. Thus, by targeting RpsA, POA may impair trans−translation, a rescue mechanism that frees ribosomes stuck in translation. 11 However, gene sequencing of PZA-resistant clinical isolates did not support these biochemical findings. 12−14 Multiple investigators failed to isolate POA-resistant mutants in vitro on acidic agar, with mutations either in fatty acid synthase I, ribosomal protein RpsA, or any other target. 9, 15 During the course of this work, Zhang and colleagues identified mutations in the aspartate decarboxylase PanD associated with PZA resistance 16, 17 and proposed this enzyme as a direct target of POA. However, PanD as a target was called into question by Dillon et al. 18 One of the major PZA conundrums is its very modest in vitro potency, contrasting with its excellent in vivo sterilizing activity. 3, 8 A second major puzzle is that genetic analyses of PZA-resistant clinical isolates do not yield any prominent clustering of PZA-associated resistance mutation patterns (other than those in the prodrug-activating pyrazinamidase). 19−21 The lack of obvious resistance epidemiology is in stark contrast to other tuberculosis drugs such as rifampicin, which inhibits RNA polymerase or the fluoroquinolones that target DNA gyrase. For those drugs, clinical resistance can be readily associated with mutations in the target enzymes, and the same mutations can be isolated in vitro. 22 New genotype-based antibiotic-resistance predicting software for TB such as Mykrobe Predictor exclude PZA specifically because of the poor predictive value. 23 The lack of clear-cut molecular resistance epidemiology or a transmission pattern in clinical PZA-resistant isolates could indicate that emerging resistant mutants may suffer from significant fitness or virulence loss in vivo and therefore cannot be found in sputum isolates. 22 Recently, the acid pH model for the mechanism of action of PZA was called into question. First, it was shown (or rediscovered 24 ) that PZA and POA also inhibit growth under nonacidic conditions in vitro. 5, 25 This was followed by the critical finding that POA does not act as a robust ionophore; i.e., intracellular acidification as a major mechanism of action appears unlikely. 25 Finally, old reports from the 1930s 26, 27 were confirmed, showing that the necrotic core of TB lesions is not acidic. 28−30 On the basis of these developments, we revisited a genetic approach and successfully selected and isolated POA-resistant mutants on nearly neutral pH media rather than acidified agar to dissect the mechanism of action of PZA. Phenotypic and molecular characterization of these mutants suggests that POA resistance can be caused by two different mechanisms: prevention of depletion of an essential cofactor and interference with the synthesis of a cell-wall-associated virulence factor.
■ RESULTS
Missense Mutations in a CoA Synthesis Gene and Loss of Function Mutations in PDIM Synthesis Genes Cause POA Resistance. We previously showed that, in contrast to common belief, PZA and POA exert growth inhibitory activity against M. tuberculosis at nearly neutral pH 6.5. 5 Here, we tested the hypothesis that employing nearly neutral instead of acidic agar, as has been attempted unsuccessfully in the past, would enable the isolation of POA-resistant mutants.
(Note that during the course of this work Zhang et al. 17 and Lanoix et al. 31 showed the feasibility of this approach. See the Discussion.) To facilitate this work, we used Mycobacterium bovis BCG as a biosafety level 2 compatible surrogate for M. tuberculosis. M. bovis BCG is naturally pyrazinamidase-negative (PncA − ) because of a point mutation (C169G/His57Asp) in the amidase gene pncA and hence is not susceptible to PZA. 4 M. bovis BCG exhibits similar susceptibility to POA in vitro under both nearly neutral (pH 6.5) and acidic (pH 5.8) conditions, with MIC 50 values of 0.5−1 and 0.25 mM, respectively (1 mM POA corresponds to 124 μg/mL).
Pilot experiments to determine broth MICs using standard (pH 6.5) growth media with and without glycerol surprisingly showed that glycerol hypersensitizes wild-type M. bovis BCG to POA (Supporting Information, Figure S1A ). Increasing the glycerol concentration from 0.01 to 0.8% resulted in a reduction of the MIC 90 of POA from 4 to 1 mM (Supporting Information, Figure S1B ). This shows that the POA susceptibility is influenced by the presence of glycerol, a phenomenon that we and others observed previously with other compound classes during antimycobacterial drug screening. 32, 33 On the basis of the observed glycerol effect, we used agar containing 0.5% glycerol or agar without glycerol, i.e., with glucose as the main carbon source, for resistant mutant selection. Four independent BCG cultures were plated on the two agar types supplemented with 1, 2, or 4 mM POA. POA-resistant colonies were observed at spontaneous resistance mutation frequencies of 10 −4 to 10
/CFU in the presence of glycerol, but in the absence of glycerol, the frequencies were 10 −3 to 10
/CFU. To confirm the resistance, a total of 26 colonies from both screens were restreaked on agar containing corresponding concentrations of POA. The resistance of the 26 strains was further confirmed by the determination of broth MICs via serial dilution in broth with and without glycerol. The POA-resistant strains could be grouped into four phenotypic classes, POA1 to POA4, according to their POA resistance levels and the effect of glycerol on resistance. (See Table 1 for  representative strains and Supporting Information, Table S1 , for other strains.)
To determine the molecular mechanisms of resistance, the 26 strains were subjected to whole genome sequencing. Rather than finding polymorphisms in the proposed POA targets fas1 and rpsA encoding the fatty acid synthase FAS I and the ribosomal protein S1, respectively, we found mutations in the aspartate decarboxylase panD involved in CoA biosynthesis 16, 17 and in the mycocerosic acid synthase mas as well as the phenolpthiocerol synthesis type-I polyketide synthases ppsA-E (Table 1 and Table  S1 ). Both Mas and PpsA-E are involved in the synthesis of the cell wall lipid phthiocerol dimycocerosate (PDIM), a virulence factor required for in vivo but not in vitro growth. 34, 35 We also found frameshift mutations in the glycerol kinase glpK that catalyzes the first step of glycerol catabolism. 36 In contrast to mutations in panD and mas or ppsA-E, mutations in glpK were specific to POA-resistant strains isolated on agar containing glycerol and were observed only in combination with mutations in mas or ppsA-E, suggesting that glpK mutations alone may not confer POA resistance.
An analysis of the whole genome sequencing results revealed that amino acid sequence-altering mutations mapped mostly to the C-terminal mycobacterium-specific putative regulatory domain of PanD. 16, 17, 37 PDIM biosynthesis genes mas and ppsA-E showed mostly frameshift and therefore likely loss-offunction mutations distributed across different domains. glpK mutations were all frameshift loss-of-function mutations. 36 The biochemical reactions catalyzed by the various enzymes and details of the mutations and their localization within the PanD, Mas/PpsA-E, and GlpK proteins are summarized in Figure 1 .
The 26 POA-resistant strains fell into 4 genotypic classes, and the genotypic classes correlated with the 4 observed phenotypic classes (Table 1 Table S1 ).
To simplify subsequent analyses, we selected one representative strain for each mutant class as shown in Table 1 :
, and POA4 [glpK1 mas-1]. The POA-resistant phenotypes for the five representative strains in media without and with glycerol can be seen in Figure 2A ,B, respectively. Glycerol sensitizes all strains to POA irrespective of genotype but to different degrees ( Figure 2B ). This results in a complete loss of resistance for low-resistance-class POA3 (mas or ppsA-E) mutants whereas the low-resistance-class POA4 mutants, containing an additional glpK mutation, retain their resistance in the presence of glycerol.
Mutant selection and all phenotypic characterizations so far were carried out at neutral pH. Because previous POA mutant Numbers in parentheses refer to the respective allele number as described in Table 1 and Table S1 . (A) PanD, aspartate decarboxylase. Domain mapping according to ref 37. (B) Mas and PpsA-E, mycocerosic acid synthase and phthiocerol polyketide synthases. Domains: PP, phosphopantetheinylate acyl carrier protein; KS, ketosynthase; AT, acyltransferase; KR, ketoreductase; DH, dehydratase; ER, enoyl reductase and C, condensation domain. 55 ,56 (C) GlpK, glycerol kinase. In contrast to mutations in panD and mas/ppsA-E that alone can confer POA resistance, glpK mutations were only observed together with mas or ppsA-E mutations and appear not to confer POA resistance by themselves. Also, in contrast to the variety of different mutations observed within panD and mas/ppsA-E, Table 1 and Table S1 show that all frameshift mutations in glpK in POA-resistant strains isolated from four independent experiments were found at the same site. Frameshift mutations at this same site were also described by refs 32, 33, and 36.
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Article selection experiments on acidic pH agar had failed to deliver resistant strains, 9, 15 we predicted that the representative POAresistant strains would exhibit their resistance at neutral pH but not at acidic pH. The results from broth dilution MICs carried out at pH 5.8 ( Figure 2C ) indeed show that POA resistance mutations do not confer POA resistance under acidic pH, which is consistent with the inability to isolate POA-resistant mutants on acidic pH agar.
POA-Resistant Mutations Also Confer PZA Resistance. In our studies, we directly used bioactive POA for the selection of resistant mutants to avoid isolating pncA mutants that constitute the vast majority of PZA resistance in vitro and in vivo. 15 To determine whether POA resistance mutations confer resistance to prodrug PZA, we introduced a functional copy of the pncA gene from M. tuberculosis H37Rv into the five representative mutants and wild-type M. bovis BCG using an integrative plasmid construct. As expected, the introduction of M. tuberculosis pncA into wild-type BCG rendered the previously PZA-resistant strain PZA-susceptible 4 ( Figure 2D ). In contrast, the five representative POA-resistant strains remained resistant to PZA after complementation with functional pncA ( Figure 2D ). Thus, the POA resistance conferring mutations also confers resistance to PZA. As observed previously with POA at acidic pH, the five representative strains complemented with functional pncA were susceptible to PZA at acidic pH 5.8 ( Figure 2E ).
To exclude the possibility that the identified POA/PZAresistant genotypes caused unspecific drug resistance, we measured the susceptibility of the five representative strains to isoniazid, rifampicin, streptomycin, and ciprofloxacin. The five POA/PZA-resistant strains were fully susceptible to the drugs, showing the same MICs as the wild-type strain (data not shown). These results indicate that POA/PZA resistance conferring mutations are drug-specific and do not cause general antibiotic resistance.
Mutations Affecting PDIM Synthesis but Not Mutations Affecting CoA Synthesis Confer Cross Resistance to POA Analogs. Nicotinic acid and benzoic acid are two structural analogs of POA, and both show antimycobacterial activity, 7 albeit with a lower potency than for POA ( Figure 3B ). Previous attempts to isolate mutants against these analogs on acidic agar were also unsuccessful. 7 The genetic data above suggest that resistance to POA may be due to two distinct mechanisms involving either panD or mas/ppsA-E mutations, the latter causing a lower level of resistance. To determine whether the analogs shared either of the two mechanisms of action with POA, cross-resistance studies were carried out. The growth of wild-type BCG was inhibited by nicotinic and benzoic acid as expected ( Figure 3A) . POA-resistant strains containing mas or ppsA-E mutations were also resistant to the analogs, whereas panD mutations alone (POA2 mutant class) did not confer crossresistance ( Figure 3A) . The results indicate that the three carboxylic acids share a PDIM synthesis-related mechanism of action whereas the CoA-related mechanism of action is unique to POA. It is interesting that glycerol in the medium hypersensitized M. bovis BCG to inhibition by benzoic acid and more weakly to nicotinic acid ( Figure 3B ), as was observed for POA.
To confirm the role of mutations in PDIM synthesis, genes in POA, and nicotinic/benzoic acid resistance, a functional copy of the mas gene, encoding the 2111 amino acid mycocerosic acid synthase, was introduced into POA-resistant strain M. bovis BCG POA3A [mas-1]. Upon complementation with functional mas, BCG POA3A [mas-1] lost its resistance to POA and reverted to wild-type susceptibility (Supporting Information, Figure S2A ). Figure S2B shows that mas complementation in BCG POA3A also restored susceptibility to nicotinic acid and benzoic acid. 
Article POA but Not POA Analogs Deplete CoA, and panD Mutations Prevent Such Depletion. What is the metabolic mechanism of the resistance mediated by panD mutations? On the basis of the nature and the location of missense mutations clustered in the C-terminal domain of PanD, we hypothesized that POA could bind to and inhibit PanD (as suggested by Zhang and colleagues 16, 17 ), causing the depletion of CoA, the final product of the biosynthetic pathway and essential acyl carrier cofactor. To test our hypothesis, we first measured the effect of POA on the cellular levels of CoA in wild-type M. bovis BCG using a fluorometric assay. Growth and CoA concentrations were measured over time in BCG cultures exposed to POA. Growth remained unaffected for 1 day after the addition of POA, indicating that POA is a slow-acting drug ( Figure 4A ). CoA levels dropped significantly between 12 and 24 h after POA treatment, suggesting that POA causes growth arrest via depletion of CoA. Figure 4C shows that in contrast to the response of wild-type bacteria to POA, the treatment of strains containing panD mutations (M. bovis BCG POA1 [panD1 mas-1] and POA2 [panD2]) did not result in the depletion of CoA. These results are consistent with the inhibition of PanD by POA, causing the depletion of CoA and thus growth termination of the bacilli. Mutations in the C-terminal domain of PanD may block POA binding and cause resistance by preventing CoA depletion. 17 To demonstrate that POA inhibits the CoA biosynthesis pathway as opposed to modulating CoA levels through a different mechanism, we measured the levels of the CoA precursor pantothenate located downstream of PanD in the pathway using LC-MS. Pantothenate displayed a CoA-like pattern: POA treatment caused the depletion of pantothenate in wild-type bacteria, whereas panD mutations prevented the POA-induced collapse of pantothenate levels ( Figure 4D ).
Our genetic and chemical probing studies suggest that the PDIM-related mechanism of action of POA is distinct from its CoA-related mechanism of action. Therefore, we hypothesized that mas or ppsA-E mutations would not prevent POA-induced CoA depletion. As predicted, strains harboring mas or ppsA-E mutations without panD comutations exhibited POA-induced CoA and pantothenate depletion similar to those of wild-type bacteria ( Figure 4C,D) . In addition, the POA analogs did not cause the depletion of CoA, consistent with their PDIM-specific mechanism and with the cross-resistance results ( Figure 4B) . Furthermore, the lack of CoA depletion at growth inhibitory concentrations of nicotinic acid and benzoic acid implies that the observed CoA depletion is POA-specific and not a general phenomenon associated with drug-induced growth inhibition.
Exogenous Pantothenate Causes Resistance to POA but Not to POA Analogs. Under our proposed model, POA inhibits PanD, which causes the depletion of CoA and therefore growth termination. Hence, we predicted that exogenous addition of the CoA precursor pantothenate would phenocopy the panD mutations. Figure 5A shows Figure 5B ). Pantothenate prevents POAmediated CoA depletion in M. bovis BCG wild type as expected 17, 18 ( Figure 5C ). Finally, consistent with our hypothesis that POA shares a CoA-unrelated, PDIM-associated mechanism of action and resistance with nicotinic acid and benzoic acid, we observed that the addition of pantothenate did not confer resistance to these POA analogs ( Figure 5D ).
CoA and PDIM Resistance Pathways Are Recapitulated in M. tuberculosis. To confirm that POA resistance conferring mutations in panD and mas or ppsA-E can also be observed in virulent M. tuberculosis upon selection in neutral pH media, we plated M. tuberculosis H37Rv on POA-containing neutral agar. Whole genome sequencing of 10 confirmed POA-resistant strains revealed missense mutations in the C-terminal domain of PanD or frameshift mutations in PDIM synthesis genes, as observed in M. bovis BCG ( Table 2 ). This suggests that the results obtained with M. bovis BCG apply to its virulent cousin. Interestingly, one POA-resistant M. tuberculosis strain carried wild-type panD and mas/ppsA-E but contained polymorphisms in dlaT, Rna60, Rv0907, and hemZ. In addition, some of the strains containing panD or ppsA-E mutations also contained mutations in genes including Rv3626c, PPE47, mmpL2, Rv1178, and mqo ( Table 2) . Because of the fact that only single mutants were obtained for these genes, it is not possible to conclude whether they are involved in POA resistance. However, these findings together with the isolation of one POA-resistant M. tuberculosis strain with wild-type panD and mas/ppsA-E alleles (Table 2) suggest that there might be additional mechanisms of resistance to be uncovered.
■ DISCUSSION
Until recently, it was believed that the tuberculosis prodrug PZA and its bioactive form POA required acidic pH to exert their antimycobacterial activity 3, 24 and that the small-molecularweight carboxylic acid POA acts as an ionophore. 6, 7 In addition, 
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Article the fatty acid synthase FAS I 9 and the ribosomal protein S1 11 were proposed as two discrete molecular targets of POA. Attempts to isolate POA-resistant mutants of M. tuberculosis on acidified agar to determine the mechanism of action were unsuccessful 9,15 until recently. 17, 31 Furthermore, it was recently shown or rediscovered that the caseum of tuberculosis lesions is not acidic, 26−29 that the drug also works at neutral pH, 5, 25 and that POA appears not to act as an ionophore as its major mechanism of action. 25 On the basis of these new findings, we revisited the genetic approach using neutral instead of acidic agar for the selection of resistant mutants and successfully isolated POA-resistant mutants in both M. bovis BCG and M. tuberculosis H37Rv.
The observed spontaneous resistance mutation frequencies ranged, dependent on the specific selection medium, from 10 /CFU. This is in the range of or is even higher than the resistance frequency for isoniazid (10 −6 38 ) and is much higher than the frequency reported for rifampicin (10 −8 39 ). The similarity between POA and isoniazid may be due to the fact that in both cases mutations in multiple genes can cause resistance and that, in some of the genes, loss-of-function mutations are allowed (see below). In contrast, rifampicin has only one major target that is essential; i.e., only very few resistance-causing polymorphisms are tolerated. 27, 39 Unexpectedly, both FAS I and ribosomal protein S1 were found to be intact from the 26 sequenced genomes of POAresistant M. bovis BCG and the 10 sequenced genomes of POAresistant M. tuberculosis H37Rv. Rather, resistance to POA appears to be caused by (i) missense mutations in the aspartate decarboxylase panD involved in the synthesis of the acyl carrier CoA and (ii) loss-of-function mutations in the polyketide synthases mas and ppsA-E involved in the synthesis of the cellenvelope-associated virulence factor PDIM. The two mechanisms appear to be additive because strains carrying double mutations in panD and mas or ppsA-E displayed a higher level of resistance. Probing for cross resistance to two structural analogs of POA, nicotinic acid and benzoic acid, showed that the analogs share the PDIM-but not the CoA-related mechanism of action with POA.
To determine the molecular basis underlying the CoA-related mechanism of resistance, we showed that POA, but not nicotinic or benzoic acid, depletes CoA in wild-type bacteria. This CoA depletion is prevented by mutations in panD but not in mas or ppsA-E. The exogenous addition of pantothenate copied the panD phenotypes, conferring resistance to POA but not to nicotinic and benzoic acid, and prevented the POA-induced depletion of intracellular CoA. Our finding that POA depletes cellular CoA may explain the reported effect of PZA on fatty acid synthesis. Jacobs and colleagues showed that PZA inhibits the synthesis of palmitic acid, 40 supporting the hypothesis that the drug inhibits FAS I. 9 However, Barry and colleagues provided evidence that this enzyme is not the direct target of the drug. 
Article This apparent contradiction may be explained by our finding that POA depletes the acyl carrier cofactor essential for fatty acid synthesis: cessation of fatty acid synthesis upon drug exposure may thus be an indirect effect of POA on CoA synthesis.
Our findings that panD missense mutations confer POA resistance, that POA depletes cellular CoA, and that POA resistance mutations in panD prevent CoA depletion are consistent with and extend recent reports by Zhang and colleagues made during the course of the current study. 16, 17 The authors attributed POA resistance to similar missense mutations in panD. Furthermore, they showed that POA inhibits aspartate decarboxylase in vitro. 17 Our collective data indicate that PZA/POA acts via inhibition of aspartate decarboxylase PanD in the CoA biosynthetic pathway. This results in depleting the pool of cellular cofactor essential in numerous pathways that use activated acyls, such as fatty acid biosynthesis, and brings growth to a halt.
In this work, we identified a second mechanism of resistance to PZA/POA involving PDIMs. PDIMs are cell-envelope-associated polyketides, which are nonessential in vitro. 41, 42 However, PDIM knockout mutants are attenuated in mouse models of infection, 34, 35 indicating that these in vitro dispensable surface molecules are virulence factors required for growth and survival in the host. If not required for in vitro growth, how are they involved in POA-mediated growth inhibition? The finding that all mas and ppsA-E POA resistance-conferring mutations were frameshift events, causing a loss of function, may provide a clue. It is conceivable that these polyketide synthases produce one or several toxic intermediates in the presence of POA (and nicotinic acid and benzoic acid). Loss-of-function mutations would then eliminate the generation of these toxic POA products and cause resistance. One may speculate that activated forms of these small carboxylic acids are incorporated into nascent PDIM polyketides in place of the correct acyl groups and thus corrupt intracellular PDIM synthesis or transport processes to the outer cell envelope. 43 Loss-of-function mutations in PDIM synthesis genes would then prevent this toxic effect and allow growth in vitro in the presence of the drug and structural analogs.
Interestingly, the newly identified PDIM-related mechanism of resistance to PZA may shed light on two major puzzles associated with this old drug: the lack of clear resistance epidemiology patterns in clinical isolates 22 and the disconnect between PZA's modest in vitro potency compared to its excellent in vivo activity 1,44−46 For most TB drugs, a reasonable correlation exists between in vitro and clinical resistance patterns, with the majority of resistance mutations in targets or activating enzymes. For PZAresistant clinical isolates, however, no such pattern has been observed other than a high frequency and diversity of pncA mutations, disabling the activation of the PZA prodrug. 19−21 Our finding that the loss of the PDIM virulence factor causes resistance may partially explain this lack of clinically observed 
Article resistance epidemiology. The in vitro isolated loss of function mutations in mas and ppsA-E might occur in patients, but the associated virulence cost is too high to sustain growth or survival in lesions and sputum; therefore, these PZA-resistant strains are not detected in clinical samples. Indeed, when we analyzed 1849 genome-sequenced M. tuberculosis clinical isolates from the genome-wide Mycobacterium tuberculosis variation (GMTV) database, we found none containing frameshift mutations in mas or ppsA-E genes. 47 We also observed the same when we looked into sequences of XDR strains from Pakistan that were pncA wild type and resistant to PZA. 48 Most TB drugs are potent antibacterials in vitro and display similar activity in vivo. In contrast, PZA's antibacterial activity in vitro is modest at best, but the drug accelerates lesion sterilization in vivo. Recently, it was suggested that the drug may act on host factors as an explanation of this disconnect. 49 However, mouse infection experiments by Grosset and colleagues suggest that host factor interference does not play a significant role in the in vivo action of the drug. 50 The authors hypothesized that if PZA has host-directed activity in addition to its antibacterial activity then this should be detectable in mice infected with PncA − -, PZA-resistant organisms. However, no such activity could be detected, pointing to a lack of host-directed activity. To demonstrate that PZA does indeed act as an antibacterial in vivo, the authors tested the efficacy of PZA in immune-deficient mice under the hypothesis that only antibacterial activity should and would be detected. Surprisingly, PZA was inactive in immune-deficient athymic nude mice infected with PncA + M. tuberculosis, where PZA cannot modulate the (absent) host's immune system. This very puzzling finding suggests that PZA works neither via its antibacterial activity nor by modulating host factors in vivo. Our finding that PZA may act as an antivirulence agent by corrupting PDIM synthesis may reconcile these observations. In standard M. tuberculosis infection models in which bacteria are PncA + and the mouse immune system is intact, PZA exposure reduces the virulence of the bacteria, and efficacy is observed. The prevention of prodrug activation in PncA − bacilli growing in immune-competent mice prevents interference with PDIM synthesis, resulting in no activity despite an intact immune system. Unmasking prodrug activation by infecting immune-deficient mice with PncA + bacteria does not restore efficacy despite the corruption of PDIM synthesis because there is no immune system to take advantage of it.
Interestingly, we observed that the addition of glycerol to standard glucose-based growth media hypersensitizes mycobacteria to POA. Consistent with this observation, low-level POA resistance of mas and ppsA-E mutants is exhibited only in glycerol-free media; in media containing glycerol, these strains are POA-susceptible. Also consistent with glycerol-induced POA hypersensitization, strains containing mas or ppsA-E mutations were resistant in the presence of glycerol when they coharbored loss-of-function mutations in glycerol kinase glpK, thereby blocking glycerol catabolism. These double mutants were isolated only on medium containing glycerol. Loss-of-function mutations in glpK seem to be insufficient to cause POA resistance on their own because these were not observed in our genetic screen. How glycerol hypersensitizes mycobacteria to POA remains an open question. Additionally, previous drug discovery programs and screens have identified compound classes that exerted glycerol-dependent activity against M. tuberculosis, 32, 33 with ∼10% of the hits showing greater potency in glycerolcontaining media. 33 The observation that the presence of glycerol increases the sensitivity of wild type and all mutant strains (albeit to different degrees), not only to POA but also to POA analogs nicotinic acid and benzoic acid (which interfere only with POA's PDIM but not the CoA-related mechanism), may indicate that glycerol catabolism creates a vulnerable metabolic state of the bacterium in which bacilli show an increased sensitivity to additional metabolic disturbances. Our previous observation that glycerol utilization induces methylglyoxal toxicity supports this notion. 32 Whether glycerol's methylglyoxal effect plays a role in the observed POA hypersensitization remains to be established. Whatever the mechanistic basis for the observed glycerol effect on POA sensitivity may be, our data suggest that the results of clinical drug susceptibility testing are likely influenced by the presence or absence of glycerol, which in addition to other assay variables 51 may contribute to the often unreliable PZA susceptibility data. 52 In conclusion, our genetic and phenotypic analyses, chemical probing with POA analogs, CoA measurements, and chemical complementation studies with pantothenate suggest that PZA/ POA has at least two distinct mechanisms of action and resistance. One involves the depletion of CoA, and resistance is caused by mutations in panD, preventing CoA depletion. These results confirm and extend recent findings suggesting PanD as target for POA/PZA. 16, 17 A novel second mechanism involves PDIM synthesis, where resistance is caused by loss-of-function mutations in PDIM synthesizing genes mas and ppsA-E. The finding that the drug may interfere with the synthesis of a virulence factor could explain pyrazinamide's excellent in vivo efficacy when compared to its modest in vitro potency, as well as the lack of clear molecular resistance epidemiology of PZA. Middlebrook albumin-dextrose-catalase (BD Difco) at 37°C with agitation at 80 rpm. Pyrazinamide, pyrazinoic acid, benzoic acid, and nicotinic acid were purchased from Sigma-Aldrich and were freshly dissolved in 90% DMSO to a concentration of 0.5 M and sterilized using 0.2 μm PTFE membrane filters (Acrodisc PALL). Kanamycin and sodium pantothenate were obtained from Sigma-Aldrich, dissolved in deionized water, and sterilized using 0.2 μm Minisart high-flow syringe filters (Sartorius) prior to adding to specific growth media under aseptic conditions. The pH of broth and liquid media after the addition of POA/NA/BA was checked using pH paper strips (Merck) and verified to be around 6.5.
Selection of Spontaneous Resistant Mutants and Growth and Resistance Determination. CFU (10 4 to 10 6 ) from mid-log-phase cultures of M. bovis BCG (M. tuberculosis) was plated on complete 7H10 agar plates or 7H10 without glycerol containing 1, 2, or 4 mM POA and grown for 4 weeks. Colonies were picked from selection plates and restreaked on agar containing the same concentration of POA for colony purification and to verify drug resistance. Isolated colonies were picked from the restreak plates and expanded in 7H9 to an OD 600 of 0.7−0.8 and stored in 25% glycerol in 1 mL aliquots at −80°C. This frozen stock was then used for the subsequent phenotypic and genetic characterization of mutants.
Growth inhibitory activities of compounds against M. bovis BCG were determined as described for M. tuberculosis in ref 5 . The MIC 90 and MIC 50 reported here are those concentrations of drug that inhibit 90 and 50% of growth, respectively, as compared to a drug-free control after 5 days of incubation. All MICs were performed in technical and biological replicates.
Whole Genome Sequencing. Genomic DNA was isolated from M. bovis BCG and M. tuberculosis H37Rv, wild type, and mutants as described. 53 Library construction using a NEBNext Ultra DNA library preparation kit (New England Biolabs), whole genome sequencing on the Illumina MiSeq platform, and bioinformatics analyses was performed by AIT Biotech, Singapore. (Details are described in Supporting Information, Supplemental methods).
pncA and mas Complementation Constructs. To restore pyrazinamidase PncA activity in M. bovis BCG, which has a nonfunctional endogenous pncA locus, the integrative vector pMV306 was used. 54 The M. tuberculosis pncA coding sequence including the putative promoter was PCR amplified using primers pncA_F 5′ATGACACCTCTGTCACCGGACGGA3′ and pncA_R 5′AAGCTTCAGGAGCTGCAAACCAACTCG-A3′ and inserted into pCR2.1TOPO by TOPO TA cloning (Life Technologies). The insert was subsequently excised using EcoRI and integrated into pMV306. The mas gene of M. bovis BCG including its putative promoter was amplified using PCR with specific primers mas_F 5′TGGTACCGGTCGGATGTGA-TGTG3′ and mas_R 5′TATCTAGAATTCGACCGCTAT-GATGCC3′ and inserted into the KpnI/XbaI restriction sites of pMV306. The integrity of the constructs was confirmed by capillary sequencing (AIT Biotech, Singapore). The constructs were electroporated into M. bovis BCG strains and selected on Kanamycin (25 μg/mL) containing 7H10 agar plates at 37°C.
Kanamycin-resistant colonies were picked after 3 weeks, expanded with Kanamycin selection, and frozen at −80°C as glycerol stock, which was subsequently characterized.
CoA Quantification. M. bovis BCG cultures were grown to mid-log phase in 1 L roller bottles (Corning) at 37°C and pelleted in 50 mL tubes at 3200 rpm for 10 min. Pellets were resuspended in the specific growth medium after adjusting to an OD 600 of 0.2 and incubated with or without POA, nicotinic acid, or benzoic acid. At each time point for each treatment, the samples were plated on 7H10 to determine CFU, and an equivalent of 2 × 10 9 CFU was pelleted by centrifugation. The pellet was resuspended in 500 μL of phosphate-buffered saline (PBS) and homogenized by bead beating (Precellys 24 homogenizer) at 6500 rpm three times for 30 s each. The lysate was pelleted by centrifugation, and the supernatant was subsequently used for analysis by a CoA assay kit (Sigma-Aldrich MAK034) per the manufacturer's instructions. The fluorescence intensity was read on a Tecan Infinite M200 plate reader (λ ex = 535 nm/λ em = 587 nm), and the CoA quantity was determined in nanomoles from a standard curve that was obtained for each experiment. These experiments were performed in technical replicates of independent biological replicates and normalized per CFU.
The lysate supernatant was also used for mass spectrometric quantification of CoA and pantothenate, which was achieved by using liquid chromatography coupled to mass spectrometry (LC-MS). 
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